Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.
Vanqua Bio has raised $45.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in July 2024.
Vanqua Bio's investors include Eli Lilly, OrbiMed, Omega Funds, Pontifax, OUP (Osage University Partners).
Vanqua Bio is headquartered in Chicago, United States.
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.
Vanqua Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vanqua Bio — Funding & Investors." VCBacked, July 5, 2024, https://www.vcbacked.co/company/vanqua-bio. Accessed October 25, 2026.
VCBacked. (2024). Vanqua Bio — Funding & Investors. Retrieved October 25, 2026, from https://www.vcbacked.co/company/vanqua-bio
{{cite web |title=Vanqua Bio — Funding & Investors |url=https://www.vcbacked.co/company/vanqua-bio |website=VCBacked |access-date=October 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated